Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group
about
High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.Direct acting antivirals for the treatment of chronic viral hepatitisTreatment of chronic hepatitis.The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysisAssociation between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapyRecent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.Management of viral hepatitis B.Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B.Hepatitis B and hepatitis C co-infection in patients with HIV.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Current pharmacotherapy for hepatitis B infection.Treatment of viral hepatitis--2001.Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbationChronic hepatitis B: current and future treatment options.Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.Hepatitis B virus resistance to lamivudine and its clinical implications.Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT levelOptimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective studyDurability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Lamivudine for chronic hepatitis B.Current therapies for chronic hepatitis B virus infection.Entecavir for the treatment of chronic hepatitis B.Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis BChronic hepatitis B: what should be the goal for new therapies?Future prospectives for the management of chronic hepatitis B.DNA-guided hepatitis B treatment, viral load is essential, but not sufficientLingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis BLong-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.Treating Immune-tolerant Hepatitis B.Pharmacotherapeutic options for hepatitis B.Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients.Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.JSH Guidelines for the Management of Hepatitis B Virus Infection.Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.Fibrosing cholestatic hepatitis possibly related to persistent parvovirus B19 infection in a renal transplant recipient.
P2860
Q24814210-63FD2BD9-EA50-4633-BD24-F625AB91BD93Q27022216-D49C7DCA-A39A-4CCC-BD50-456A8BEBDD2FQ28364240-898C3318-78D2-44A8-89F4-79C8E66C76F9Q28533788-6BE904FA-9FC8-4E7B-9E4F-7F9CAA8B904FQ30390865-310383F9-8956-4F0A-909C-F283D4F554DAQ33492413-DD800CC3-4400-4872-8870-DF71397B3633Q33947160-214F43DC-A1D5-488C-87CA-26A9BE106FDAQ33959006-D17FF918-8953-49F3-B32A-BBBFEF5C5D94Q33989405-214AF266-C3E8-4394-9E5A-044F6C6DF6ADQ34323219-0B8331A4-9156-4284-B9C0-C93C6059F8A3Q34382067-4C1F77EF-DF8B-4FDF-815A-FD3271497A97Q34390231-48686477-10AE-4262-8902-EB5A389AC6CAQ34390398-C55CEED8-F6A8-4169-A7B7-5BF38B29CB61Q34553545-ED0CBC70-0A4A-4F67-868D-E9BC1ABD81D6Q34687438-82C27ADB-A805-43F1-BC74-8A212A639100Q34785877-B7C7B5F5-17C3-414A-B8CB-B3DCDBD13BADQ35007583-CFB154C9-E2FF-4697-822B-B570EA161901Q35045329-BA489BC4-9AFA-4E38-A0BF-2EFA59C34E87Q35487430-27C3741E-1ADC-4D34-AD34-4B7F00072834Q35595469-7D0BCB63-ECF1-4C4B-A52C-736806953D4CQ35917357-933A36C0-3851-47C8-B5A8-061C4F3BD336Q35917541-BE16CDCD-F741-4022-84D8-72E9041B9ACFQ35964745-C93BDA9C-646D-453B-B7A3-94F1D84150DFQ36474696-99DE4C73-0A89-40EB-ADFC-8F3224B268AFQ36769986-9B3EC6C1-0F49-416B-9896-C4A979E465F4Q36841719-6E26B09B-B0AB-4AC9-BCC8-3A5C90F40C77Q37122325-1F8F1D59-BD95-43DC-90F0-ABDEC7411D0EQ37154736-DF083095-0E66-4BBC-9C6E-44DDCD986494Q37356782-D68035AC-228D-4EA3-A4C7-9E3A48977F5EQ37425703-2344B5EB-4D08-43E5-B90F-4958B291A16EQ37482902-A497FD38-5984-41A7-9633-E7EBA95792C4Q37511410-B5E1A973-3E34-411A-8B59-2145933C1D68Q38086312-731BC048-9369-45CF-99AF-871608562AA0Q38271430-45C42111-0290-4909-8C10-7C52A6BE2F7EQ38631076-5747BD0C-71A5-46E0-9373-649006ECDD44Q39243598-B0E26F26-BE71-464B-986E-6740F8C9701EQ40433719-34C7BDC9-CC87-422D-ABB6-82BF2025B706Q42244740-1F136B8F-ABBF-4C2E-B3F3-204A71FB749CQ43203665-F1519AB2-F116-4E84-AE54-F7AB9AFEB1C3Q43627419-C052EA36-51FF-4292-BF9F-956B84562B28
P2860
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@ast
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@en
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@nl
type
label
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@ast
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@en
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@nl
prefLabel
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@ast
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@en
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@nl
P2093
P356
P1433
P1476
Pretherapy alanine transaminas ...... patitis Lamivudine Trial Group
@en
P2093
P356
10.1002/HEP.510300313
P407
P577
1999-09-01T00:00:00Z